Rule 3.8A

Appendix 3E

Daily share buy-back notice (except minimum holding buy-back and selective buy-back)

Information and documents given to ASX become ASX's property and may be made public.

	ne of entity	ABN/ARSN 15 088 417 403		
Sig	ma Pharmaceuticals Limited			
We	(the entity) give ASX the following	information.		
Inf	formation about buy-back			
1	Type of buy-back	On-market buy-back		
2	Date Appendix 3C was given to ASX	(Associated Appendix	3D dated 2 October	
		2014)		
	tal of all shares/units bought ve been received, before, and	back, or in relation to	o which acceptances Previous day	
	9	back, or in relation to on, previous day	_	
	9	back, or in relation to on, previous day	-	

	Before p	reviou	s day	Previous day
et buy-	Highest \$0.8525	price	paid:	Highest price paid: \$0.7800
	Lowest \$0.5600	price	paid:	Lowest price paid: \$0.7650 Highest price allowed under rule 7.33: \$0.7959

5 If buy-back is an on-market buy-

How many shares/units may still be bought back?

6 If the company/trust has disclosed an intention to buy back a maximum number of shares/units – the remaining number of shares/units to be bought back

22,729,223			

Compliance statement

- 1. The company is in compliance with all Corporations Act requirements relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

or, for trusts only:

- 1. The trust is in compliance with all requirements of the Corporations Act as modified by Class Order 07/422, and of the trust's constitution, relevant to this buy-back.
- 2. There is no information that the listing rules require to be disclosed that has not already been disclosed, or is not contained in, or attached to, this form.

Sign here:

Date: 27 October 2014

(Director/Company secretary)

Print name: SUE MORGAN

== == == ==